ArticleGut2004
Systemic antibodies towards mucosal bacteria in ulcerative colitis and Crohn's disease differentially activate the innate immune response.
Article in Gut, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 43 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Synbiotic Treatment in Crohn's Disease Patients
Synbiotic Treatment of Ulcerative Colitis Patients
Who cites it
43 citing papers in PubMed, 86 citations in OpenAlex.
- Serological profiling of Crohn's disease and ulcerative colitis patients reveals anti-microbial antibody signatures.World journal of gastroenterology · 2022Trial
- Long-term alteration of intestinal microbiota in patients with ulcerative colitis by antibiotic combination therapy.PloS one · 2014Trial
- Specificity vs. Synergy Between Single-Strain and Multi-Strain Probiotics for Ulcerative Colitis Treatment: A Review of the Literature.Biomedicines · 2026Review
- Chitosan nanoparticles of rutin mitigated histological changes induced in DNCB-induced colitis by enhanced modulation of inflammation and oxidative stress.Journal of molecular histology · 2025Article
- Inflammatory Bowel Disease from the Perspective of Newer Innate Immune System Biomarkers.Gastrointestinal disorders (Basel, Switzerland) · 2025Article
- Leaky gut, circulating immune complexes, arthralgia, and arthritis in IBD: coincidence or inevitability?Frontiers in immunology · 2024Article
- Differences in Faecal Microbiome Taxonomy, Diversity and Functional Potential in a Bovine Cohort Experimentally Challenged withAnimals : an open access journal from MDPI · 2023Article
- Probiotic Therapy During Vaccination Alters Antibody Response to Simian-Human Immunodeficiency Virus Infection But Not to Commensals.AIDS research and human retroviruses · 2023Article
- The systemic anti-microbiota IgG repertoire can identify gut bacteria that translocate across gut barrier surfaces.Science translational medicine · 2022Article
- Article
- Article
- Ursolic Acid Regulates Intestinal Microbiota and Inflammatory Cell Infiltration to Prevent Ulcerative Colitis.Journal of immunology research · 2021Article
- Effects of herb-partitioned moxibustion for ulcerative colitis: A protocol for systematic review and meta-analysis.Medicine · 2020Article
- Immunological mechanisms underpinning faecal microbiota transplantation for the treatment of inflammatory bowel disease.Clinical and experimental immunology · 2020Review
- Pathogenicity of Enterococci.Microbiology spectrum · 2019Review
- Humoral immune responses against gut bacteria in dogs with inflammatory bowel disease.PloS one · 2019Article
- Complex Bacterial Consortia Reprogram the Colitogenic Activity ofFrontiers in immunology · 2019Article
- Bacterial Signaling at the Intestinal Epithelial Interface in Inflammation and Cancer.Frontiers in immunology · 2017Review
- Dysregulation of Systemic and Mucosal Humoral Responses to Microbial and Food Antigens as a Factor Contributing to Microbial Translocation and Chronic Inflammation in HIV-1 Infection.PLoS pathogens · 2017Article
- A New Chinese Medicine Intestine Formula Greatly Improves the Effect of Aminosalicylate on Ulcerative Colitis.Evidence-based complementary and alternative medicine : eCAM · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
aimsThe mucosa in ulcerative colitis (UC) is replete with antibody producing plasma B cells and polymorphonuclear leucocytes (PMN). This combination of effector cells requires a crosslinking antigen to evoke an antibody driven PMN inflammatory response via their Fc receptors. The stimulus for activation is thought to be commensal bacteria colonising the gut mucosa. The aim of this investigation was to compare the principal culturable bacterial populations on the rectal mucosa of UC patients, and to determine whether specific antibodies towards these bacteria can activate infiltrating PMN through opsonisation. This would provide an explanation for this chronic inflammatory condition.
methodsBacteria colonising rectal tissue were characterised using chemotaxonomic techniques. Systemic antibody responses were measured against total antigens and surface antigens of these organisms in UC and Crohn's disease (CD) patients, together with healthy controls. Antibody enhancement of the respiratory burst in PMN was also investigated, against a range of mucosal isolates.
resultsDistinct differences were observed in some bacterial populations in UC biopsies, which were generally reflected in antibody responses towards these organisms. UC patients had higher IgG responses to surface antigens, primarily IgG1, whereas the response in CD was mainly IgG2. Antibodies from UC patients greatly enhanced the respiratory burst in PMN, in response to individual bacterial species.
conclusionsChanges in mucosal bacteria, and a switch from internal to surface antigen/antibody reactivity of a predominantly IgG1 type, leads to greater opsonisation of the respiratory burst in PMN, providing a mechanism for maintaining the inflammatory state in UC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.